Skip to content

Valneva

US · VALN #3677 by market cap Listed 2021
5.78 +0.09 +1.58%
Live - 5344 symbols - heartbeat 50s ago · 2026-10-09 16:04

Valuation each multiple against its own 5-year range

P/B ratio 6.13 Expensive vs history 73rd percentile
5-year average 6.34 · #407 of 513 in Biotechnology
P/E ratio -2.91 Expensive vs history 89th percentile
5-year average -9.13 · forward -35.50
P/S ratio 3.48 Expensive vs history 72nd percentile
5-year average 4.06 · forward 2.29 · #77 of 387 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Valneva (VALN) 548.08M -2.87 6.03 0.00%
Vertex Pharmaceuticals (VRTX) 129.29B 29.71 6.39 0.00%
Moderna (MRNA) 89.83B -28.20 13.29 0.00%
Regeneron Pharmaceuticals (REGN) 76.86B 18.47 2.42 0.49%
argenx SE (ARGX) 51.88B 31.43 6.16 0.00%
Revolution Medicines (RVMD) 40.67B -21.39 15.61 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value11.71 Economic moatNone UncertaintyVery High

Trading 102.6% below Morningstar's fair value estimate.

Fair value

While Valneva SE may seem inexpensive after its substantial price decline over the past year, we've limited its rating to 3 stars to account for the possibility that it may represent a value trap. The stock currently trades at a 50% discount to our quantitative fair value estimate of $11.71 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's balance sheet increases our quantitative valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of -2.9, which lies in the bottom 20% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.

On a different note, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to revenue ratio of 4.0, for example, sits in the top 40% compared with peers globally. This overstates the long-term cash flow growth potential of the organization. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-09 16:04:05 · For reference only, not investment advice and not tailored to your situation.

Valneva discussion 0 comments

Add a comment